macular degeneration

(redirected from Stargardt's macular degeneration)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Stargardt's macular degeneration: Fundus Flavimaculatus

macular degeneration

n.
A condition in which the cells of the macula lutea degenerate, causing blurred vision and ultimately blindness.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

macular degeneration

n
(Pathology) pathological changes in the macula lutea, resulting in loss of central vision: a common cause of blindness in the elderly
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

mac′ular degenera′tion


n.
degeneration of the macula in the center of the retina, resulting in a loss of central vision but not affecting peripheral vision.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.macular degeneration - eye disease caused by degeneration of the cells of the macula lutea and results in blurred visionmacular degeneration - eye disease caused by degeneration of the cells of the macula lutea and results in blurred vision; can cause blindness
degeneration, devolution - the process of declining from a higher to a lower level of effective power or vitality or essential quality
eye disease - any disease of the eye
age-related macular degeneration, AMD - macular degeneration that is age-related
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

macular degeneration

n degeneración f macular
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Ocata intends to use the money for general corporate purposes including the initiation of the Phase 2 dry age-related macular degeneration (AMD) and pivotal Stargardt's macular degeneration (SMD) clinical studies and the advancement of its promising preclinical programs.
suspensions and sheets of cells), for use as therapeutic agents, as well as the use of these formulations for treating ophthalmic diseases, including dry age related macular degeneration and Stargardt's macular degeneration.
The three new patents extend protection to include all formats and formulations of RPE cells, including suspensions and sheets of cells, for use as therapeutic agents, and the use of these formulations for treating ophthalmic diseases such as dry age related macular degeneration (dry AMD) and Stargardt's macular degeneration (SMD).